The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties
Open accessAbstract
Several novel anti-CD20 monoclonal antibodies are currently in development with the aim of improving the treatment of B cell malignancies. Mutagenesis and epitope mapping studies have revealed differences between the CD20 epitopes recognized by these antibodies. Recently, X-ray crystallography studies confirmed that the Type I CD20 antibody rituximab and the Type II CD20 antibody obinutuzumab (GA101) differ fundamentally in their interaction with CD20 despite recognizing a partially overlapping epitope on CD20. The Type I CD20 antibodies rituximab and ofatumumab are known to bind to different epitopes. The differences suggest that the biological properties of these antibodies are not solely determined by their core epitope sequences, but also depend on other factors, such as the elbow hinge angle, the orientation of the bound antibody and differential effects mediated by the Fc region of the antibody. Taken together, these factors may explain differences in the preclinical properties and clinical efficacy of anti-CD20 antibodies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
Hiddemann, W. (2005) · Blood · doi:10.1182/blood-2005-01-0016 · Cited by 1,320
Weng, W.-K., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300
Witzig, T. E., Gordon, L. I., Cabanillas, F., Czuczman, M. S., Emmanouilides, C., Joyce, R., Pohlman, B. L., Bartlett, N. L., Wiseman, G. A., Padre, N., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.076 · Cited by 1,170
Shields, R. L., Namenuk, A. K., Hong, K., Meng, Y. G., Rae, J., Briggs, J., Xie, D., Lai, J., Stadlen, A., Li, B., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009483200 · Cited by 1,161
Salles, G., Seymour, J. F., Offner, F., López-Guillermo, A., Belada, D., Xerri, L., Feugier, P., Bouabdallah, R., Catalano, J. V., Brice, P., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62175-7 · Cited by 1,079
Characterization of a human B lymphocyte-specific antigen.
Stashenko, P., Nadler, L. M., Hardy, R., & Schlossman, S. F. (1980) · The Journal of Immunology · doi:10.4049/jimmunol.125.4.1678 · Cited by 1,076
Mössner, E., Brünker, P., Moser, S., Püntener, U., Schmidt, C., Herter, S., Grau, R., Gerdes, C., Nopora, A., van Puijenbroek, E., et al. (2010) · Blood · doi:10.1182/blood-2009-06-225979 · Cited by 981
Self-citationMarcus, R. (2005) · Blood · doi:10.1182/blood-2004-08-3175 · Cited by 967
Koene, H. R., Kleijer, M., Algra, J., Roos, D., E.G.Kr. von dem Borne, A., & de Haas, M. (1997) · Blood · doi:10.1182/blood.v90.3.1109 · Cited by 794
Dreyling, M., Campo, E., Hermine, O., Jerkeman, M., Le Gouill, S., Rule, S., Shpilberg, O., Walewski, J., & Ladetto, M. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx223 · Cited by 741
Teeling, J. L. (2004) · Blood · doi:10.1182/blood-2004-01-0039 · Cited by 630
The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20
Teeling, J. L., Mackus, W. J. M., Wiegman, L. J. J. M., van den Brakel, J. H. N., Beers, S. A., French, R. R., van Meerten, T., Ebeling, S., Vink, T., Slootstra, J. W., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.1.362 · Cited by 609
van Oers, M. H. J., Klasa, R., Marcus, R. E., Wolf, M., Kimby, E., Gascoyne, R. D., Jack, A., van't Veer, M., Vranovsky, A., Holte, H., et al. (2006) · Blood · doi:10.1182/blood-2006-05-021113 · Cited by 592
Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
Wierda, W. G., Kipps, T. J., Mayer, J., Stilgenbauer, S., Williams, C. D., Hellmann, A., Robak, T., Furman, R. R., Hillmen, P., Trneny, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3187 · Cited by 590
Kaminski, M. S., Zelenetz, A. D., Press, O. W., Saleh, M., Leonard, J., Fehrenbacher, L., Lister, T. A., Stagg, R. J., Tidmarsh, G. F., Kroll, S., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.19.3918 · Cited by 584
Forstpointner, R. (2004) · Blood · doi:10.1182/blood-2004-04-1323 · Cited by 580
Witzig, T. E., White, C. A., Wiseman, G. A., Gordon, L. I., Emmanouilides, C., Raubitschek, A., Janakiraman, N., Gutheil, J., Schilder, R. J., Spies, S., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.12.3793 · Cited by 539
From the bench to the bedside: ways to improve rituximab efficacy
Cartron, G., Watier, H., Golay, J., & Solal-Celigny, P. (2004) · Blood · doi:10.1182/blood-2004-03-1110 · Cited by 523
Mechanisms of killing by anti-CD20 monoclonal antibodies
Glennie, M. J., French, R. R., Cragg, M. S., & Taylor, R. P. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2007.06.151 · Cited by 515
Forstpointner, R., Unterhalt, M., Dreyling, M., Bock, H.-P., Repp, R., Wandt, H., Pott, C., Seymour, J. F., Metzner, B., Hanel, A., et al. (2006) · Blood · doi:10.1182/blood-2006-04-016725 · Cited by 467
Morschhauser, F., Radford, J., Van Hoof, A., Vitolo, U., Soubeyran, P., Tilly, H., Huijgens, P. C., Kolstad, A., d’Amore, F., Diaz, M. G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.2015 · Cited by 460
Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts
Cragg, M. S., Morgan, S. M., Chan, H. T. C., Morgan, B. P., Filatov, A. V., Johnson, P. W. M., French, R. R., & Glennie, M. J. (2003) · Blood · doi:10.1182/blood-2002-06-1761 · Cited by 390
The Biology of CD20 and Its Potential as a Target for mAb Therapy
Cragg, M. S., Walshe, C. A., Ivanov, A. O., & Glennie, M. J. (2004) · Current Directions in Autoimmunity · doi:10.1159/000082102 · Cited by 364
Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents
Cragg, M. S., & Glennie, M. J. (2004) · Blood · doi:10.1182/blood-2003-06-2031 · Cited by 360
The Carbohydrate at FcγRIIIa Asn-162
Ferrara, C., Stuart, F., Sondermann, P., Brünker, P., & Umaña, P. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510171200 · Cited by 354
Self-citationBeers, S. A., French, R. R., Chan, H. T. C., Lim, S. H., Jarrett, T. C., Vidal, R. M., Wijayaweera, S. S., Dixon, S. V., Kim, H., Cox, K. L., et al. (2010) · Blood · doi:10.1182/blood-2010-01-263533 · Cited by 335
van Oers, M. H. J., Van Glabbeke, M., Giurgea, L., Klasa, R., Marcus, R. E., Wolf, M., Kimby, E., van t Veer, M., Vranovsky, A., Holte, H., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.5827 · Cited by 328
Alduaij, W., Ivanov, A., Honeychurch, J., Cheadle, E. J., Potluri, S., Lim, S. H., Shimada, K., Chan, C. H. T., Tutt, A., Beers, S. A., et al. (2011) · Blood · doi:10.1182/blood-2010-07-296913 · Cited by 294
Lim, S. H., Vaughan, A. T., Ashton-Key, M., Williams, E. L., Dixon, S. V., Chan, H. T. C., Beers, S. A., French, R. R., Cox, K. L., Davies, A. J., et al. (2011) · Blood · doi:10.1182/blood-2011-01-330357 · Cited by 267
Wiseman, G. A., Gordon, L. I., Multani, P. S., Witzig, T. E., Spies, S., Bartlett, N. L., Schilder, R. J., Murray, J. L., Saleh, M., Allen, R. S., et al. (2002) · Blood · doi:10.1182/blood.v99.12.4336 · Cited by 264
Anti-CD20 monoclonal antibodies: historical and future perspectives
Lim, S. H., Beers, S. A., French, R. R., Johnson, P. W. M., Glennie, M. J., & Cragg, M. S. (2010) · Haematologica · doi:10.3324/haematol.2008.001628 · Cited by 244
Niederfellner, G., Lammens, A., Mundigl, O., Georges, G. J., Schaefer, W., Schwaiger, M., Franke, A., Wiechmann, K., Jenewein, S., Slootstra, J. W., et al. (2011) · Blood · doi:10.1182/blood-2010-09-305847 · Cited by 230
Self-citationBowles, J. A., Wang, S.-Y., Link, B. K., Allan, B., Beuerlein, G., Campbell, M.-A., Marquis, D., Ondek, B., Wooldridge, J. E., Smith, B. J., et al. (2006) · Blood · doi:10.1182/blood-2006-04-020057 · Cited by 227
Chan, H. T. C., Hughes, D., French, R. R., Tutt, A. L., Walshe, C. A., Teeling, J. L., Glennie, M. J., & Cragg, M. S. (2003) · PubMed · Cited by 211
Gordon, L. I., Molina, A., Witzig, T., Emmanouilides, C., Raubtischek, A., Darif, M., Schilder, R. J., Wiseman, G., & White, C. A. (2004) · Blood · doi:10.1182/blood-2003-11-3883 · Cited by 189
Beers, S. A., Chan, C. H. T., James, S., French, R. R., Attfield, K. E., Brennan, C. M., Ahuja, A., Shlomchik, M. J., Cragg, M. S., & Glennie, M. J. (2008) · Blood · doi:10.1182/blood-2008-04-149161 · Cited by 180
Ivanov, A., Beers, S. A., Walshe, C. A., Honeychurch, J., Alduaij, W., Cox, K. L., Potter, K. N., Murray, S., Chan, C. H. T., Klymenko, T., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37884 · Cited by 177
Keating, G. M. (2010) · Drugs · doi:10.2165/11201110-000000000-00000 · Cited by 175
Stein, R., Qu, Z., Chen, S., Rosario, A., Shi, V., Hayes, M., Horak, I. D., Hansen, H. J., & Goldenberg, D. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0493 · Cited by 171
Morschhauser, F., Leonard, J. P., Fayad, L., Coiffier, B., Petillon, M.-O., Coleman, M., Schuster, S. J., Dyer, M. J. S., Horne, H., Teoh, N., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.9117 · Cited by 164
Polyak, M. J., & Deans, J. P. (2002) · Blood · doi:10.1182/blood.v99.9.3256 · Cited by 159
The Radioisotope Contributes Significantly to the Activity of Radioimmunotherapy
Davis, T. A., Kaminski, M. S., Leonard, J. P., Hsu, F. J., Wilkinson, M. J., Zelenetz, A. D., Wahl, R. L., Kroll, S., Coleman, M., Goris, M. L., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0756 · Cited by 152
Rapid Redistribution of CD20 to a Low Density Detergent-insoluble Membrane Compartment
Deans, J. P., Robbins, S. M., Polyak, M. J., & Savage, J. A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.1.344 · Cited by 151
CD20 Homo-oligomers Physically Associate with the B Cell Antigen Receptor
Polyak, M. J., Li, H., Shariat, N., & Deans, J. P. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800784200 · Cited by 150
Structural Basis for Recognition of CD20 by Therapeutic Antibody Rituximab
Du, J., Wang, H., Zhong, C., Peng, B., Zhang, M., Li, B., Huo, S., Guo, Y., & Ding, J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m701654200 · Cited by 134
Honeychurch, J., Alduaij, W., Azizyan, M., Cheadle, E. J., Pelicano, H., Ivanov, A., Huang, P., Cragg, M. S., & Illidge, T. (2012) · Blood · doi:10.1182/blood-2011-12-395541 · Cited by 133
Dreyling, M. H., Ghielmini, M. E. G., Marcus, R. E., Salles, G., & Vitolo, U. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr388 · Cited by 130
Goldenberg, D. M., Rossi, E. A., Stein, R., Cardillo, T. M., Czuczman, M. S., Hernandez‐Ilizaliturri, F. J., Hansen, H. J., & Chang, C. (2008) · Blood · doi:10.1182/blood-2008-07-168146 · Cited by 128
Beum, P. V., Lindorfer, M. A., Beurskens, F. J. M., Stukenberg, P. T., Lokhorst, H. M., Pawluczkowycz, A. W., Parren, P. W. H. I., van de Winkel, J. G. J., & Taylor, R. P. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.1.822 · Cited by 127
Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study
Czuczman, M. S., Fayad, L., Delwail, V., Cartron, G., Jacobsen, E. D., Kuliczkowski, K., Link, B. K., Pinter‐Brown, L. C., Radford, J. A., Hellmann, A. R., et al. (2012) · Blood · doi:10.1182/blood-2011-09-378323 · Cited by 126
Perosa, F., Favoino, E., Caragnano, M. A., & Dammacco, F. (2005) · Blood · doi:10.1182/blood-2005-04-1769 · Cited by 110
Lemery, S. J., Zhang, J., Rothmann, M. D., Yang, J., Earp, J. C., Zhao, H., McDougal, A. J., Pilaro, A. M., Chiang, R., Gootenberg, J. E., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0570 · Cited by 97
Li, B., Zhao, L., Guo, H., Wang, C., Zhang, X., Wu, L., Chen, L., Tong, Q., Qian, W., Wang, H., et al. (2009) · Blood · doi:10.1182/blood-2009-06-225474 · Cited by 88
Du, J., Yang, H., Guo, Y., & Ding, J. (2009) · Molecular Immunology · doi:10.1016/j.molimm.2009.04.009 · Cited by 82
Johnson, N. A., Leach, S. R., Woolcock, B. W., deLeeuw, R. J., Bashashati, A., Sehn, L. H., Connors, J. M., Chhanabhai, M., Brooks-Wilson, A. R., & Gascoyne, R. D. (2009) · Haematologica · doi:10.3324/haematol.2008.001024 · Cited by 72
Tilly, H., & Dreyling, M. H. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq203 · Cited by 71
Forero, A., de Vos, S., Pohlman, B. L., Pashkevich, M. A., Cronier, D. M., Dang, N. H., Carpenter, S. P., Allan, B. W., Nelson, J. G., Slapak, C. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0850 · Cited by 66
Bartolucci, P., Murr, T. E., Roudot‐Thoraval, F., Habibi, A., Santin, A., Renaud, B., Noël, V., Michel, M., Bachir, D., Galactéros, F., et al. (2009) · Blood · doi:10.1182/blood-2009-06-227330 · Cited by 60
Czuczman, M. S., Heß, G., Gadeberg, O., Pedersen, L. M., Goldstein, N., Gupta, I. V., Jewell, R. C., Lin, T. S., Lisby, S., Strange, C., et al. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09086.x · Cited by 58
Jak, M., van Bochove, G. G. W., Reits, E. A., Kallemeijn, W. W., Tromp, J. M., Umaña, P., Klein, C., van Lier, R. A. W., van Oers, M. H. J., & Eldering, E. (2011) · Blood · doi:10.1182/blood-2011-01-331702 · Cited by 49
Self-citationDevelopment of novel humanized anti‐CD20 antibodies based on affinity constant and epitope
Uchiyama, S., Suzuki, Y., Otake, K., Yokoyama, M., Ohta, M., Aikawa, S., Komatsu, M., Sawada, T., Kagami, Y., Morishima, Y., et al. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01392.x · Cited by 46
CD20-Directed Small Modular Immunopharmaceutical, TRU-015, Depletes Normal and Malignant B Cells
Hayden-Ledbetter, M. S., Cerveny, C., Espling, E., Brady, W., Grosmaire, L. S., Tan, P., Bader, R., Slater, S., Nilsson, C. A., Barone, D., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1694 · Cited by 46
Bonavida, B. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.984 · Cited by 44
Crystal structure of chimeric antibody C2H7 Fab in complex with a CD20 peptide
Du, J., Wang, H., Zhong, C., Peng, B., Zhang, M., Li, B., Hou, S., Guo, Y., & Ding, J. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2008.01.034 · Cited by 40
Radioimmunotherapy in follicular lymphoma
Illidge, T., & Morschhauser, F. (2011) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2011.03.005 · Cited by 31
Casulo, C., Vose, J. M., Ho, W., Kahl, B. S., Brunvand, M. W., Goy, A. H., Kasamon, Y. L., Cheson, B. D., & Friedberg, J. W. (2014) · Clinical Immunology · doi:10.1016/j.clim.2014.06.005 · Cited by 26
Nishida, M., Usuda, S., Okabe, M., Miyakoda, H., Komatsu, M., Hanaoka, H., Teshigawara, K., & Niwa, O. (2007) · International Journal of Oncology · doi:10.3892/ijo.31.1.29 · Cited by 20
Herter, S., Waldhauer, I., Otz, T., Herting, F., Lang, S., Nicolini, V., Römmele, M., Friess, T., van Puijenbroek, E., Bacac, M., et al. (2010) · Blood · doi:10.1182/blood.v116.21.3925.3925 · Cited by 8
Self-citationBeyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphoma
Sikder, M. A., & Friedberg, J. W. (2008) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-008-0027-5 · Cited by 7
Cited by
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
Hauser, S. L., Bar-Or, A., Comi, G., Giovannoni, G., Hartung, H.-P., Hemmer, B., Lublin, F., Montalban, X., Rammohan, K. W., Selmaj, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1601277 · Cited by 2,021
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
Montalban, X., Hauser, S. L., Kappos, L., Arnold, D. L., Bar-Or, A., Comi, G., de Seze, J., Giovannoni, G., Hartung, H.-P., Hemmer, B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606468 · Cited by 1,905
Antibody Structure and Function: The Basis for Engineering Therapeutics
Chiu, M. L., Goulet, D. R., Teplyakov, A., & Gilliland, G. L. (2019) · Antibodies · doi:10.3390/antib8040055 · Cited by 638
Considerations for the Design of Antibody-Based Therapeutics
Goulet, D. R., & Atkins, W. M. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.05.031 · Cited by 302
Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics
Golay, J., Semenzato, G., Rambaldi, A., Foà, R., Gaidano, G., Gamba, E., Pane, F., Pinto, A., Specchia, G., Zaja, F., et al. (2013) · mAbs · doi:10.4161/mabs.26008 · Cited by 148
Metadata
- Authors
- Klein, C., Lammens, A., Schäfer, W., Georges, G., Schwaiger, M., Mössner, E., Hopfner, K.-P., Umaña, P., & Niederfellner, G.
- Venue
- mAbs
- Publisher
- Informa UK Limited
- Published
- 2013-01
- Volume
- 5
- Issue
- 1
- Pages
- 22-33
- ISSN
- 1942-0862 (ISSN-L)
- 1942-0870
- OpenAlex
- W2042725832
- Cited by
- 392
- References
- 70
- FWCI
- 11.88
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.